On Feb. 28, 2024, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor (11 to 1; 1 abstain) to recommend that individuals aged 65 and older should receive an additional dose of 2023-2024 Formula COVID-19 vaccine (four months since receipt of the last dose). ACIP’s recommendation will now be considered for adoption by the CDC. Doses of the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) are available at major retail pharmacies nationwide and can be ordered through one of their distribution partners for physician use in the non-retail setting.
While the recent recommendation focuses on protection for older adults who are at increased risk of COVID-19, information shared at the recent ACIP meeting also reinforces the ongoing benefit of vaccination for all those who are eligible. Data from clinical trials continue to show broad long-lived neutralization responses to currently circulating forward-drift variants including JN.1 and JN.4 for Novavax’s protein-based non-mRNA COVID-19 vaccine, while maintaining a favorable side effect profile. Peer-reviewed real-world effectiveness data is being published that shows the immune responses seen in our trials translates into COVID-19 prevention in the real world.1
Those interested in a non-mRNA protein-based vaccine should ask their pharmacists about Novavax at major retail pharmacies nationwide including, but not limited to, Albertsons, CVS Pharmacy and Rite Aid. Doses can be located on us.novavaxcovidvaccine.com or vaccines.gov.
